AbCellera Biologics Inc (ABCL)
2.83
-0.12
(-4.07%)
USD |
NASDAQ |
Nov 26, 16:00
2.87
+0.04
(+1.41%)
After-Hours: 04:52
AbCellera Biologics Enterprise Value: 192.75M for Nov. 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 26, 2024 | 192.75M |
| November 25, 2024 | 228.19M |
| November 22, 2024 | 172.07M |
| November 21, 2024 | 160.26M |
| November 20, 2024 | 145.49M |
| November 19, 2024 | 157.30M |
| November 18, 2024 | 139.58M |
| November 15, 2024 | 139.58M |
| November 14, 2024 | 172.07M |
| November 13, 2024 | 219.33M |
| November 12, 2024 | 231.15M |
| November 11, 2024 | 287.26M |
| November 08, 2024 | 154.35M |
| November 07, 2024 | 160.26M |
| November 06, 2024 | 172.07M |
| November 05, 2024 | 160.26M |
| November 04, 2024 | 210.47M |
| November 01, 2024 | 163.21M |
| October 31, 2024 | 163.21M |
| October 30, 2024 | 177.40M |
| October 29, 2024 | 192.16M |
| October 28, 2024 | 209.87M |
| October 25, 2024 | 159.69M |
| October 24, 2024 | 153.79M |
| October 23, 2024 | 177.40M |
| Date | Value |
|---|---|
| October 22, 2024 | 195.11M |
| October 21, 2024 | 174.45M |
| October 18, 2024 | 203.96M |
| October 17, 2024 | 147.88M |
| October 16, 2024 | 130.17M |
| October 15, 2024 | 112.46M |
| October 14, 2024 | 100.66M |
| October 11, 2024 | 121.32M |
| October 10, 2024 | 94.75M |
| October 09, 2024 | 91.80M |
| October 08, 2024 | 115.42M |
| October 07, 2024 | 133.13M |
| October 04, 2024 | 94.75M |
| October 03, 2024 | 88.85M |
| October 02, 2024 | 88.85M |
| October 01, 2024 | 115.42M |
| September 30, 2024 | 124.27M |
| September 27, 2024 | 98.72M |
| September 26, 2024 | 83.99M |
| September 25, 2024 | 48.63M |
| September 24, 2024 | 72.20M |
| September 23, 2024 | 60.41M |
| September 20, 2024 | 92.83M |
| September 19, 2024 | 137.03M |
| September 18, 2024 | 139.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.89M
Minimum
Sep 06 2024
15.55B
Maximum
Dec 11 2020
2.579B
Average
1.667B
Median
Sep 27 2022
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 898.34M |
| Edesa Biotech Inc | 5.136M |
| Lexaria Bioscience Corp | 24.79M |
| InMed Pharmaceuticals Inc | -2.33M |
| Xenon Pharmaceuticals Inc | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.11M |
| Revenue (Quarterly) | 6.507M |
| Total Expenses (Quarterly) | 96.68M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -785.4% |
| Earnings Yield | -21.55% |
| Normalized Earnings Yield | -21.55 |